RandyW Posted April 29, 2008 Share Posted April 29, 2008 Poniard reports positive results for lung cancer drug Associated Press 04.23.08, 3:50 PM ET Popular Videos Billionaires Charge Into Deals Credit Crunch Spillover Most Wanted On The Run Tribeca Film Festival 2008 Summer Movies' Secret Weapon Related Quotes PARD 3.63 - 0.03 Most Popular Stories Young Billionaires Easily Overlooked Tax Deductions The No-Tech Hacker Job Hunting In A Downturn How To Tap Lenders When Credit Is Tight SOUTH SAN FRANCISCO, Calif. - Poniard Pharmaceuticals Inc. said Wednesday its lung cancer drug picoplatin continued to extend patient survival in mid-stage studies. The company said the latest results confirmed older findings in patients with small cell lung cancer who did not respond to chemotherapy or whose cancer progressed despite other initial treatments. Cancer patients taking picoplatin lived a median of 27 weeks, the company said, compared with 14 weeks of survival for patients undergoing standard care. Poniard said it plans to continue testing its drug in late-stage trials with a launch goal of 2010. Shares of Poniard Pharmaceuticals Inc. rose 17 cents, or 4.8 percent, Wednesday to $3.70. Copyright 2008 Associ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.